Connect Biopharma Holdings Ltd
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| Incorporation by Reference | ||||||
|---|---|---|---|---|---|---|
| Exhibit No. | Description | Form | File No. | Exhibit Reference | Filing Date | Filed or Furnished Herewith |
| 3.1 | Fifth Amended and Restated Memorandum of Association of Connect Biopharma Holdings Limited | 20-F | 001-40212 | 1.1 | 3/31/2022 | |
| 4.1 | Specimen Certificate for Ordinary Shares | F-1/A | 333-253631 | 4.1 | 3/12/2021 | |
| 4.2 | Description of Securities | Filed | ||||
| 10.1† | Form of Indemnification Agreement | F-1/A | 333-253631 | 10.2 | 3/17/2021 | |
| 10.2† | 2019 Stock Incentive Plan | F-1 | 333-253631 | 10.1 | 2/26/2021 | |
| 10.3† | 2021 Stock Incentive Plan and form of share option grant notice and share option agreement thereunder | F-1/A | 333-253631 | 10.3 | 3/12/2021 | |
| 10.4† | 2021 Employee Share Purchase Plan | F-1/A | 333-253631 | 10.4 | 3/12/2021 | |
| 10.5† | Non-Employee Director Compensation Program | 10-Q | 001-40212 | 10.1 | 8/13/2025 | |
| 10.6† | 2024 Employment Inducement Incentive Award Plan and form of share option grant notice and share option agreement thereunder | 6-K | 001-40212 | 10.1 | 6/12/2024 | |
| 10.7† | Employment Agreement, effective as of June 12, 2024, between Connect Biopharm LLC and its affiliates and Barry Quart | 6-K | 001-40212 | 10.2 | 6/12/2024 | |
| 10.8† | Employment Agreement, effective as of June 12, 2024, between Connect Biopharm LLC and its affiliates and David Szekeres | 6-K | 001-40212 | 10.3 | 6/12/2024 | |
| 10.9† | Employment Offer Letter, dated August 7, 2024, between Connect Biopharm LLC and Lisa Peraza | 10-K | 001-40212 | 10.15 | 3/31/2025 | |
| 10.10† | Addendum to Employment Offer Letter for Severance Benefits, dated August 7, 2024, between Connect Biopharm LLC and Lisa Peraza | 10-K | 001-40212 | 10.16 | 3/31/2025 | |
| 10.11* | Exclusive License and Collaboration Agreement, dated November 21, 2023, by and among Connect Biopharma HongKong Limited, Suzhou Connect Biopharma Co., Ltd. and Simcere Pharmaceutical Co., Ltd. (English Translation) | 6-K | 001-40212 | 99.1 | 11/21/2023 | |
| 10.12 | Lease, effective as of October 25, 2024, by and between Connect Biopharm LLC and Gateway Torrey Hills LLC | 10-K | 001-40212 | 10.18 | 3/31/2025 | |
| 19.1 | Insider Trading Compliance Policy | 10-K | 001-40212 | 19.1 | 3/31/2025 | |
| 21.1 | Subsidiaries of the Registrant | Filed | ||||
| 23.1 | Consent of Independent Registered Public Accounting Firm | Filed | ||||
| 24.1 | Power of Attorney (included on the signature page of this report) | Filed | ||||
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed | ||||
| 32.1# | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished | ||||
| 97† | Policy for Recovery of Erroneously Awarded Compensation | 20-F | 001-40212 | 97 | 4/16/2024 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | Filed | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Filed | ||||
| 101.DEF | Inline XBRL Taxonomy Definition Linkbase Document | Filed | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | Filed | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101) | Filed | ||||
†Management contract or compensatory plan, contract or arrangement.
Certain portions of this exhibit (indicated by “[**]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
#The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.